Andrew Alliance is a technology company.
Andrew Alliance provides pipetting tools and software for scientific laboratories, enhancing precision and reproducibility in lab workflows.
Andrew Alliance has raised $14.0M across 1 funding round.
Andrew Alliance has raised $14.0M in total across 1 funding round.
Andrew Alliance has raised $14.0M in total across 1 funding round.
Andrew Alliance's investors include Omega Funds.
Andrew Alliance is a technology company specializing in the development of intelligent robotic systems and connected devices for laboratory automation. Its flagship product is the Andrew+ Pipetting Robot and the Pipette+ Intelligent Pipetting System, which automate and standardize liquid handling tasks in scientific labs. These solutions serve research scientists and laboratory professionals by enabling reproducible, fully traceable experiments through automation of complex workflows without requiring robotics expertise. The company’s cloud-based software platform, OneLab, allows users to design, execute, and track experiments intuitively, enhancing productivity and data quality in life sciences research[1][2][3].
Founded in 2011 and headquartered in Vernier, Switzerland, Andrew Alliance has demonstrated growth momentum through product innovation and industry recognition, including multiple awards for new product innovation and design. The company was acquired by Waters Corporation in 2020, reflecting its strategic value in advancing laboratory automation technologies[1][2][4].
Andrew Alliance was founded in March 2011 by a team focused on addressing the challenges of manual pipetting in laboratories, which is prone to variability and errors. The founders leveraged their expertise in robotics and software to create a solution that integrates conventional pipettes with intelligent automation. The launch of the first Andrew Pipetting Robot in 2013 marked a pivotal moment, establishing the company’s presence in the lab automation market. Subsequent development led to the second-generation Andrew+ system, which further enhanced automation capabilities and connectivity through the OneLab software ecosystem[1][2][4].
Andrew Alliance rides the growing trend of laboratory automation and digitalization in life sciences, driven by the need for reproducibility, data integrity, and efficiency in research workflows. The timing is critical as scientific research increasingly demands scalable, automated solutions to handle complex experiments and large data volumes. Market forces such as the rise of personalized medicine, biotechnology innovation, and regulatory requirements for traceability favor Andrew Alliance’s connected robotic systems. By enabling scientists to automate without robotics expertise, Andrew Alliance influences the broader ecosystem by democratizing access to advanced lab automation and fostering collaboration through its software platform[2][3].
Looking ahead, Andrew Alliance is positioned to expand its influence by integrating more advanced automation capabilities and broadening its device ecosystem within the OneLab platform. Trends such as AI-driven experiment design, increased connectivity, and sustainability will shape its journey. As part of Waters Corporation, Andrew Alliance can leverage greater resources to accelerate innovation and market penetration. Its continued focus on user-friendly, traceable automation solutions will likely enhance reproducibility and efficiency in life sciences research, reinforcing its role as a key enabler in the digital transformation of laboratories[1][2][4].
Andrew Alliance has raised $14.0M across 1 funding round. Most recently, it raised $14.0M Series C in June 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2018 | $14.0M Series C | Omega Funds |